You're using an outdated browser. This website will not display correctly and some features will not work.
Learn more about the browsers we support for a faster and safer online experience.

Important: This version of the e-Laws website will be upgraded to a new version in the coming weeks.
You can try the beta version of the new e-Laws at ontario.ca/laws-beta.

Health Protection and Promotion Act

R.R.O. 1990, REGULATION 569

REPORTS

Historical version for the period June 23, 2023 to June 30, 2023.

Last amendment: 172/23.

Legislative History: 606/91, 749/91, 233/92, 84/95, 1/05, 503/05, 377/06, 274/07, 426/07, 306/08, 141/15, 148/17, 498/17, 138/18, 7/20, 318/20, 744/20, 157/21, 338/21, 462/22, CTR 22 JL 22 - 1, 172/23.

This is the English version of a bilingual regulation.

1. (1) A report required under section 25, 26 or 27 of the Act shall, with respect to the person to whom the report relates, contain the following information:

1. Name and address in full and, if available, any other contact information.

2. Date of birth in full.

3. Sex.

4. Date of onset of symptoms.  R.R.O. 1990, Reg. 569, s. 1 (1); O. Reg. 498/17, s. 1.

(2) A person who makes a report under section 25 or 26 or subsection 27 (1) or (2) of the Act and gives the information set out in subsection (1) shall, upon the request of the medical officer of health, give to the medical officer of health such additional information respecting the disease of public health significance or communicable disease, as the case may be, as the medical officer of health considers necessary.  R.R.O. 1990, Reg. 569, s. 1 (2); O. Reg. 1/05, s. 1 (1); O. Reg. 138/18, s. 1 (1).

(3) Despite subsection (1), a report under section 25 or 26 of the Act with respect to leprosy shall be made in the form entitled “Form 3 – Notification of New Active – Leprosy (Hansen’s Disease)”, dated January 2017 and available on the website of the Government of Ontario Central Forms Repository under the listing for the Ministry of Health and Long-Term Care.  O. Reg. 1/05, s. 1 (2); O. Reg. 148/17, s. 1.

2. A report required under section 28 of the Act shall, with respect to the pupil to whom the report relates, contain the following information:

1. Name and address in full.

2. Date of birth in full.

3. Sex.

4. Name and address in full of the school that the pupil attends.  R.R.O. 1990, Reg. 569, s. 2.

3. (1) A report made under subsection 29 (1) of the Act shall, with respect to the person to whom the finding was made, be made within 24 hours of the making of the finding and shall contain the following information:

1. Name and address in full.

2. Date of birth in full.

3. Sex.

4. Date when the specimen was taken that yielded the positive finding.

5. Name and address in full of the physician, registered nurse in the extended class, dentist or other health care provider as indicated on the most recent test requisition. O. Reg. 498/17, s. 2.

(2) A report made under subsection 29 (1) of the Act shall contain the following information with respect to a person to whom a finding of Hepatitis C was made, if available, in addition to the information required under subsection (1) of this section:

1. Results of Hepatitis C serologic tests from the time of the first positive confirmed Hepatitis C serologic test, back to, and including, the most recent negative result.

2. Results of all Hepatitis C RNA tests including any initial tests and any tests done at any time subsequent to the initial test.

3. The date of specimen collection and the date the final test result was reported. O. Reg. 498/17, s. 2.

3.1 (1) Subject to the same exemptions that would apply under section 5.1, the operator of a laboratory shall report every finding that indicates the presumptive presence of a disease of public health significance to the medical officer of health in the area in which the person who gives rise to the case resides.  O. Reg. 426/07, s. 2; O. Reg. 141/15, s. 1; O. Reg. 138/18, s. 1 (1).

(2) A report made under subsection (1) shall, with respect to the person to whom the finding was made, be made within twenty-four hours of the making of the finding and shall contain the following information:

1. Name and address in full.

2. Date of birth in full.

3. Sex.

4. Date when the specimen was taken that yielded the presumptive finding.

5. Name and address in full of the physician, registered nurse in the extended class or dentist attending the person.

6. Any additional information that the medical officer of health considers necessary from the reporting laboratory respecting the disease of public health significance or communicable disease.  O. Reg. 426/07, s. 2; O. Reg. 498/17, s. 3; O. Reg. 138/18, s. 1 (2).

4. A report made under section 30 of the Act shall, with respect to the deceased, contain the following information:

1. Name and address in full.

2. Date of birth in full.

3. Date of death in full.

4. Name and address in full of the physician or registered nurse in the extended class who attended the deceased.  R.R.O. 1990, Reg. 569, s. 4; O. Reg. 426/07, s. 3.

5. A report under section 25 or 26 of the Act shall contain the following information in addition to the information required under subsection 1 (1):

1. Syphilis:

i. The date of diagnosis.

ii. The name and address of the physician or registered nurse in the extended class attending the person.

iii. The name of the hospital and the date of admission if the person is admitted to a hospital or the name of the hospital and the date of each visit if the person is seen as an out-patient of the hospital.

iv. Duration, stage and site of infection.

v. Drugs and dosage used for previous treatment, if any, of the infection.

vi. If previous treatment given, the place, date and physician or registered nurse in the extended class responsible for the administration of the treatment.

vii. Current treatment, if any, of the infection, setting out the drugs and dosage used.

viii. If current treatment is being given, the place, date and physician or registered nurse in the extended class responsible for the administration of treatment.

ix. Laboratory findings and investigative tests including, without being limited to, serological tests, microscopic examination and cerebrospinal fluid examinations, together with the results of the tests.

x. Contacts.

xi. Risk factors.

xii. Revoked: O. Reg. 498/17, s. 4 (1).

2. Chancroid, Chlamydia trachomatis infections, Gonorrhoea:

i. The date of diagnosis.

ii. The name and address of the physician or registered nurse in the extended class attending the person.

iii. The name of the hospital, the date of admission and the date of discharge if the person is admitted to hospital.

iv. Place where infection is believed to have been acquired.

v. Contacts.

vi. Revoked: O. Reg. 498/17, s. 4 (2).

vii. The agent of disease.

viii. Medical condition of the person including signs and symptoms of the infection.

ix. The case classification of the person.

x. Laboratory findings and investigative tests including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.

xi. The source of infection including history of exposures.

xii. Risk factors for the disease.

xiii. Travel history, both within and outside Canada.

xiv. Initial treatment, if any, of the infection, including, without being limited to, the drugs and dosage used.

xv. If initial treatment has been given, the place, date and physician or registered nurse in the extended class responsible for administration of treatment.

xvi. Final effective treatment including, without being limited to, the drugs and dosage used.

xvii. If effective treatment has been given, the place, date and physician or registered nurse in the extended class responsible for administration of treatment.

xviii. The date of death and relation of the infection to the cause of death, if the person is deceased.

3. Acquired Immune Deficiency Syndrome (AIDS):

i. The date of diagnosis.

ii. The name and telephone number of the physician or registered nurse in the extended class attending the person.

iii. The name of the hospital if the person is admitted to a hospital or is an outpatient.

iv. Medical conditions of the person including laboratory findings and date of onset of symptoms that are indicative of Acquired Immune Deficiency Syndrome.

v. Other medical conditions of the person that may have caused immuno-suppression (exclusion criteria).

vi. Country of birth, date of arrival in Canada, race and residence of the person at onset of illness.

vii. Current status of person infected (alive or dead) (if dead give date of death).

viii. Risk factors.

ix.-xii. Revoked: O. Reg. 498/17, s. 4 (4).

4. Hemorrhagic fevers, including Lassa Fever, Ebola virus disease, Marburg virus disease and Hemorrhagic fevers from other viral causes and Plague:

i. The date of diagnosis.

ii. The name and address of the physician or registered nurse in the extended class attending the person.

iii. The name of the hospital and the date of admission if the person is admitted to a hospital.

iv. Travel history, both within and outside Canada.

v. Exposure to any of the following (Give date and time along with details relating to personal protective equipment used, if any):

A. Known reservoir of the pathogen (for example, bats, rodents, monkeys).

B. Persons with a similar illness.

C. Virus in a laboratory.

vi. Clinical history:

A. Date of onset of illness.

B. Symptoms and signs of the illness.

C. Rule out other causes of febrile illness, including, without being limited to, malaria.

vii. Revoked: O. Reg. 498/17, s. 4 (5).

viii. Laboratory specimens.

A. List all specimens collected by type and date.

B. Name of laboratory where specimens may be located.

ix. State if ambulance was used and date of use.

5. Acute Flaccid Paralysis, Chickenpox (Varicella), Diphtheria, Haemophilus influenza, all types, invasive, Measles, Meningococcal disease, invasive, Mumps, Pertussis (Whooping Cough), Pneumococcal disease, invasive, Poliomyelitis, acute, Rubella, Rubella, congenital syndrome, Tetanus:

i. The date of the diagnosis.

ii. The agent of disease.

iii. The name and address of the physician or registered nurse in the extended class attending the person.

iv. Medical condition and status of the person, including signs, symptoms and site, if any, of the infection.

v. The clinical history of the person, including:

A. The name of the hospital, date of admission and the date of discharge from the hospital if the person is admitted to hospital, or the name of the hospital if the person is seen as an out-patient of the hospital.

B. The date and duration of isolation, if isolated.

C. Full vaccination history pertaining to the disease in question, including type of vaccine or vaccines and date or dates of receipt.

vi. The case classification of the person.

vii. Laboratory findings and other investigative tests including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.

viii. Association with outbreak and outbreak number, if applicable.

ix. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.

x. Completion of the course of treatment, including the major mode of therapy and the treatment compliance.

xi. Place where infection is believed to have been acquired.

xii. The source of infection, including history of exposures and potential for community transmission.

xiii. Risk factors.

xiv. The immigration status and origin of the person, including:

A. Country of birth.

B. Country of last residence.

C. Date of arrival in Canada.

D. Immigration status at time of arrival in Canada.

xv. Travel history, both within and outside Canada.

xvi. The employment details of the person, including job title and place of employment.

xvii. The name and address of the school the person attends, if applicable, including the classroom.

xviii. Contacts.

xix. Number of contacts traced (excluding Tetanus, Pneumococcal disease, invasive and Acute Flaccid Paralysis).

xx. Outcome:

A. If the person is deceased, date and cause of death.

B. Complications.

C. Absconded — lost to follow-up before treatment completion.

D. Other.

6. Tuberculosis:

i. The date of the diagnosis.

ii. The agent of disease.

iii. The name and address of the physician or registered nurse in the extended class attending the person.

iv. Medical condition and status of the person including signs, symptoms and site, if any, of the infection.

v. The clinical history of the person, including:

A. The name of the hospital, date of admission and the date of discharge from the hospital if the person is admitted to hospital or the name of the hospital if the person is seen as an out-patient of the hospital.

B. The date and duration of isolation, if isolated.

C. Vaccination history.

D. Reactivation of old disease and years of previous treatment setting out the drugs and dosages used and the dates treatment commenced and ended.

vi. The case classification of the person.

vii. Laboratory findings and investigative tests including, without being limited to, culture and antimicrobial sensitivity, serological tests, X-ray examination, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.

viii. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.

ix. Completion of the course of treatment including the major mode of therapy (Directly Observed Therapy — daily or intermittent or Daily, self-administered) and the treatment compliance estimate (80%, 50-79%, less than 50% or unknown).

x. Risk factors.

xi. The immigration status and origin of the person, including:

A. Country of birth.

B. Country of last residence.

C. Date of arrival in Canada.

D. Unique Client Identifier number (“UCI#”) or Immigration Medical Examination number (“IME#”) if UCI# is unknown.

E. Date reported for medical surveillance (has made contact with, or been contacted by, the health unit, if applicable).

F. Date clinically assessed as per post-landing immigration medical surveillance requirements, if applicable.

G. Immigration status at time of arrival in Canada.

H. Country of birth of parents if person is under 20 years of age and Canadian born non-Indigenous.

xii. The Indigenous status of the person.

xiii. Travel history, both within and outside Canada.

xiv. The employment details of the person, including job title and place of employment.

xv. The name and address of the school the person attends, if applicable, including the classroom.

xvi. Contacts.

xvii. Outcome:

A. If the person is deceased, date of death and cause of death.

B. Complications.

C. Absconded — lost to follow-up before treatment completion.

D. Other.

xviii.-xxv. Revoked: O. Reg. 498/17, s. 4 (7).

7. Group B Streptococcal Disease, neonatal, Ophthalmia Neonatorum:

i. The date of the diagnosis.

ii. The name and address of the physician or registered nurse in the extended class attending the person.

iii. The name of the hospital, the date of admission and the date of discharge if the person is admitted to hospital.

iv. Contacts.

v. Medical condition of the person, including signs and symptoms of the infection.

vi. The case classification of the person.

vii. Laboratory findings and other investigative tests, including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.

viii. Initial treatment, if any, of the infection, including, without being limited to, the drugs and dosage used.

ix. Final effective treatment, including, without being limited to, the drugs and dosage used.

x. Risk factors.

xi. The date of death and relation of the infection to the cause of death, if deceased.

8. Revoked: O. Reg. 138/18, s. 2 (3).

9. Group A Streptococcal disease, invasive:

i. The date of the diagnosis.

ii. The agent of disease.

iii. The name and address of the physician or registered nurse in the extended class attending the person.

iv. Medical condition and status of the person including clinical severity, signs, symptoms and site, if any, of the infection.

v. The clinical history of the person, including:

A. The name of the hospital, date of admission and the date of discharge from the hospital if the person is admitted to hospital.

B. The date and duration of isolation, if isolated.

vi. The case classification of the person.

vii. Laboratory findings and investigative tests including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.

viii. Association with outbreak and outbreak number, if applicable.

ix. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.

x. Antibiotic resistance, if applicable.

xi. Risk factors.

xii., xiii. Revoked: O. Reg. 498/17, s. 4 (10).

xiv. The employment details of the person including job title and place of employment.

xv. The name and address of the school the person attends, if applicable, including the classroom.

xvi. Contacts.

xvii.- xxi. Revoked: O. Reg. 498/17, s. 4 (11).

xxii. The date of death and relation of the infection to the cause of death, if the person is deceased.

10. Influenza – novel, non-seasonal:

i. The date of diagnosis.

ii. The agent of disease, including subtype.

iii. The name and address of the physician or registered nurse in the extended class attending the person.

iv. Medical condition and status of the person, including signs, symptoms and site, if any, of the infection.

v. The clinical history of the person, including:

A. The name of the hospital, date of admission and the date of discharge from the hospital if the person is admitted to hospital, or the name of the hospital if the person is seen as an out-patient of the hospital.

B. The date and duration of isolation, if isolated.

C. Vaccination history.

vi. The case classification of the person.

vii. Laboratory findings, including, without being limited to, antigen detection, culture and viral strain identification, genetic typing and serological tests.

viii. Association with outbreak and outbreak number, if applicable.

ix. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.

x. Risk factors.

xi. Travel history, both within and outside Canada.

xii. The employment details of the person, including job title and place of employment.

xiii. The name and address of the school the person attends, if applicable, including the classroom.

xiv. Contacts.

xv. The date of death and relation of the infection to the cause of death, if the person is deceased.

11. Diseases caused by a novel coronavirus, including Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and coronavirus disease (COVID-19):

i. The date of the diagnosis.

ii. The agent of disease.

iii. The name and address of the physician or registered nurse in the extended class attending the person.

iv. Medical condition and status of the person including signs, symptoms and site, if any, of the infection.

v. The clinical history of the person, including:

A. The name of the hospital, date of admission and the date of discharge from the hospital if the person is admitted to hospital, or transferred to another hospital or the name of the hospital if the person is seen as an out-patient of the hospital.

B. The date and duration of isolation, if isolated.

C. The date and duration of quarantine, if quarantined.

D. Vaccination history.

vi. The case classification of the person.

vii. The date of any change of case classification and details of the change.

viii. Laboratory findings and investigative tests including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination, X-ray examination and cerebrospinal fluid examination, together with the results of the tests.

ix. Association with outbreak and outbreak number, if applicable.

x. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.

xi. Place where infection is believed to have been acquired.

xii. The source of infection including history of exposures, and potential for community transmission.

xiii. Risk factors.

xiv. Travel history, both within and outside Canada.

xv. List places and method of travel within Canada prior to and since the onset of illness.

xvi. The employment details of the person including job title and place of employment.

xvii. The name and address of the school the person attends, if applicable, including the classroom.

xviii. Health unit responsible for identifying contacts.

xix. Contacts.

xx. Race.

xxi. Income level.

xxii. Household size.

xxiii. Language.

xxiv. Revoked: O. Reg. 498/17, s. 4 (15).

xxv. The date of death and relation of the infection to the cause of death, if deceased.

12. Gastroenteritis and respiratory infection outbreaks in institutions and public hospitals:

i. The name and address of the institution or hospital, as the case may be, and the contact person.

ii. The agent of disease, if known.

iii. The onset date and clinical details of symptoms in first and last cases.

iv. A description of the outbreak and an outbreak definition, including, without being limited to, a description of symptoms and laboratory findings.

v. The date the outbreak was declared and the outbreak number, if applicable.

vi. The date the outbreak was declared over.

vii. The total number of cases in residents or patients and all persons who carry on activities in the facility, including, but not limited to, employees, nurses, students, physicians, registered nurses in the extended class, contract workers and volunteers.

viii. The total number of cases in residents and staff of the institution who were admitted to hospital.

ix. The total number of outbreak-related deaths during the outbreak period.

x. Laboratory findings (etiologic agent/subtyping).

xi. Current treatment, if any, of the residents of the institution exhibiting signs and symptoms consistent with the outbreak, setting out the drugs used and the date treatment commenced.

xii. Measures taken to monitor the institution for signs and symptoms consistent with the outbreak in persons who are residents or staff of the institution, including the line list which shall include the name and location of residents and staff within the institution exhibiting signs and symptoms consistent with the description of the outbreak, including clinical details and when the symptoms commenced.

xiii. Number of residents and staff in the entire institution and in areas of the institution affected by the outbreak.

xiv. The details of any notification made to any other institution or hospital regarding the declaration of an outbreak in the institution or hospital for the purposes of preventing the spread of infection.

xv. Infection control measures utilized to minimize the impact of the outbreak on the residents and staff of the institution and to prevent the spread of the infection, including, but not limited to, influenza immunization, exclusion of non-immunized persons from the institution, the use of antiviral medications, isolation of ill persons, increased environmental sanitation and restriction of visitors.

xvi. For outbreaks in institutions, verification of staff immunization policies.

13. Encephalitis, including primary, viral, post-infectious, vaccine-related, subacute sclerosing panencephalitis, unspecified, and Meningitis, acute:

i. The date of the diagnosis.

ii. The agent of disease.

iii. The name and address of the physician or registered nurse in the extended class attending the person.

iv. Medical condition and the current status of the person including signs and symptoms.

v. The name of the hospital and the date of admission and the date of discharge if the person is admitted to hospital or the name and date of visits if the person is seen as an out-patient of the hospital.

vi. The case classification of the person.

vii. The outcome of the disease.

viii. Laboratory findings and investigative tests including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.

ix. Association with outbreak and outbreak number, if applicable.

x. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.

xi. Place where infection is believed to have been acquired.

xii. The source of infection including history of exposures.

xiii. Risk factors.

xiv. Travel history, both within and outside Canada.

xv. Revoked: O. Reg. 498/17, s. 4 (18).

xvi. The employment details of the person including job title and place of employment.

xvii. The name and address of the school the person attends, if applicable, including classroom.

xviii. The date of death and relation of the infection to the cause of death, if deceased.

14. Hepatitis B, Hepatitis C:

i. The date of the diagnosis.

ii. The agent of disease.

iii. The name and address of the physician or registered nurse in the extended class attending the person.

iv. The name of the hospital, the date of admission and the date of discharge if the person is admitted to hospital or the name of the hospital if the person is seen as an out-patient of the hospital.

v. History of immunization, including number of doses and date of receipt and post exposure prophylaxis, including the use of Hepatitis B immune globulin, as appropriate.

vi. The case classification of the person.

vii. Laboratory findings and investigative tests, including, without being limited to, serological tests, together with the results of the tests.

viii. Association with outbreak and outbreak number, if applicable.

ix. The source of infection including history of exposures.

x. Risk factors.

xi. Place where infection is believed to have been acquired.

xii. Travel history, both within and outside Canada.

xiii. The employment details of the person including job title and place of employment, if applicable.

xiv. The name and address of the school the person attends, if applicable, including classroom.

xv. Contacts.

xvi. Revoked: O. Reg. 498/17, s. 4 (24).

xvii. The date of death and relation of the infection to the cause of death, if deceased.

15. Creutzfeldt-Jakob Disease, all types:

i. The date of the diagnosis.

ii. The name and address of the physician or registered nurse in the extended class attending the person.

iii. The name of the hospital and the date of admission if the person is admitted to a hospital or is seen as an out-patient of the hospital.

iv. Laboratory findings and investigative tests including, without being limited to, 14-3-3 protein test, cerebrospinal fluid examination, microscopic examination, electroencephalogram, magnetic resonance imaging, computerized axial tomography and biopsy, together with the results of the tests.

v. History and physical examination findings of the person.

vi. Dates of organ, blood or blood product donated or received.

vii. Name of institution where performed, and dates, with respect to invasive procedures to person including, without being limited to, lumbar puncture, surgery and endoscopy.

viii. Countries of residence and duration of residence or travel.

ix. Genetic history of transmissible spongiform encephalopathy.

x. Date of death, if the person is deceased.

xi. Autopsy findings.

16. Amebiasis, Anthrax, Blastomycosis, Botulism, Brucellosis, Campylobacter enteritis, Cholera, Cryptosporidiosis, Cyclosporiasis, Echinococcus multilocularis infection, Food poisoning — all causes, Giardiasis, Hantavirus Pulmonary Syndrome, Hepatitis A viral infections, Legionellosis, Listeriosis, Lyme Disease, Paralytic Shellfish Poisoning, Paratyphoid Fever, Psittacosis/Ornithosis, Q Fever, Rabies, Salmonellosis, Shigellosis, Trichinosis, Tularemia, Typhoid Fever, West Nile Virus Illness, Verotoxin-producing E. coli infection indicator conditions, including Haemolytic Uraemic Syndrome (HUS), Yersiniosis:

Note: On July 1, 2023, paragraph 16 of section 5 of the Regulation is amended by striking out the portion before subparagraph i and substituting the following: (See: O. Reg. 172/23, s. 1)

16. Amebiasis, Anaplasmosis, Anthrax, Babesiosis, Blastomycosis, Botulism, Brucellosis, Campylobacter enteritis, Cholera, Cryptosporidiosis, Cyclosporiasis, Echinococcus multilocularis infection, Food poisoning — all causes, Giardiasis, Hantavirus Pulmonary Syndrome, Hepatitis A viral infections, Legionellosis, Listeriosis, Lyme Disease, Paralytic Shellfish Poisoning, Paratyphoid Fever, Powassan virus, Psittacosis/Ornithosis, Q Fever, Rabies, Salmonellosis, Shigellosis, Trichinosis, Tularemia, Typhoid Fever, Verotoxin-producing E. coli infection indicator conditions, including Haemolytic Uraemic Syndrome (HUS), West Nile Virus Illness, Yersiniosis:

i. The date of the diagnosis.

ii. The agent of disease.

iii. The name and address of the physician or registered nurse in the extended class attending the person.

iv. Medical condition of the person including signs and symptoms of the infection.

v. The name of the hospital and the date of admission and the date of discharge if the person is admitted to hospital or the name of the hospital if the person is seen as an out-patient of the hospital.

vi. The case classification of the person.

vii. Laboratory findings and investigative tests including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.

viii. Association with outbreak and outbreak number, if applicable.

ix. Current treatment, if any, of the infection, setting out the drugs and dosage used and the dates treatment commenced and ended.

x. Risk factors, including exposure to known reservoirs or vectors, as applicable.

xi. Travel history, both within and outside Canada.

xii. Contacts.

xiii. Revoked: O. Reg. 498/17, s. 4 (27).

xiv. The immigration status and origin of the person, including:

A. Country of birth.

B. Country of last residence.

C. Date of arrival to Canada.

xv. Revoked: O. Reg. 498/17, s. 4 (28).

xvi. The employment details of the person including job title and place of employment.

xvii. The name and address of the school the person attends, if applicable, including classroom.

xviii. The outcome of the disease.

xix. The date of death and relation of the infection to the cause of death, if the person is deceased.

17. Smallpox and other orthopoxviruses, including monkeypox:

i. The date of the diagnosis.

ii. The agent of disease.

iii. The name and address of the physician or registered nurse in the extended class attending the person.

iv. Medical condition and status of the person including signs and symptoms of the infection.

v. The clinical history of the person, including:

A. The name of the hospital, date of admission and the date of discharge from the hospital if the person is admitted to hospital, or transferred to another hospital or the name of the hospital if the person is seen as an out-patient of the hospital.

B. The date and duration of isolation, if isolated.

C. The date and duration of quarantine, if quarantined.

D. Vaccination history.

vi. The case classification of the person.

vii. The date of any change of case classification and details of the change.

viii. Laboratory findings and investigative tests including, without being limited to culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.

ix. Revoked: O. Reg. 498/17, s. 4 (29).

x. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.

xi. Place, including geographical location, where infection is believed to have been acquired.

xii. The source of infection including history of exposures and potential for community transmission.

xiii. Risk factors.

xiv. Travel history, both within and outside Canada.

xv. Revoked: O. Reg. 498/17, s. 4 (30).

xvi. The employment details of the person including job title and place of employment.

xvii. The name and address of the school the person attends, if applicable, including the classroom.

xviii. Contacts.

  xix.-xxiv. Revoked: O. Reg. 498/17, s. 4 (31).

xxv. The date of death and relation of the infection to the cause of death, if deceased. R.R.O. 1990, Reg. 569, s. 5; O. Reg. 1/05, s. 2; O. Reg. 426/07, s. 4; O. Reg. 148/17, ss. 2, 4; O. Reg. 498/17, s. 4; O. Reg. 138/18, s. 2; O. Reg. 7/20, s. 1; O. Reg. 318/20, s. 1; O. Reg. 744/20, s. 1; O. Reg. 462/22, s. 1.

5.1 (1) In this section,

“AIDS” means Acquired Immune Deficiency Syndrome; (“sida”)

“HIV” means Human Immunodeficiency Virus. (“VIH”)  O. Reg. 749/91, s. 1.

(2) A physician or registered nurse in the extended class who provides professional services to a patient in a clinic set out in Schedule 1 and who is required to report under section 26 of the Act following a test to determine if the patient is infected with an agent of AIDS is exempt from reporting the patient’s name and address if, before the test was ordered, the patient received counselling about preventing the transmission of HIV infection.  O. Reg. 749/91, s. 1; O. Reg. 84/95, s. 1 (1); O. Reg. 377/06, s. 1 (1); O. Reg. 426/07, s. 5.

(3) The operator of a laboratory is exempt from reporting, under section 29 of the Act, the name and address of a person who has tested positive for an agent of AIDS if the test is in relation to professional services provided at a clinic set out in Schedule 1.  O. Reg. 749/91, s. 1; O. Reg. 84/95, s. 1 (2); O. Reg. 377/06, s. 1 (2).

(4) A physician, registered nurse in the extended class or operator of a laboratory is exempt from reporting, under section 26 or 29 of the Act, the name and address of a patient with respect to whom a subsequent viral load test is conducted after an initial test was conducted at a clinic set out in Schedule 1. O. Reg. 141/15, s. 2.

5.2 A report under subsection 27 (1) of the Act in respect of Clostridium difficile infection (CDI) outbreaks in public hospitals shall contain the following information in addition to the information required under subsection 1 (1):

1. The name and address of the hospital and the contact person.

2. The agent of disease.

3. The date the outbreak was declared, the date the outbreak was declared over, and the outbreak number.

4. The onset date of the index case and of the last case.

5. The total number of cases.

6. The total number of deaths in cases associated with the outbreak during the outbreak period.

7. Disease control measures utilized to minimize the impact of the outbreak and to prevent the spread of disease.

8. Quantification of the population at risk for the disease in the entire hospital and in the area affected by the outbreak during the outbreak period including, without being limited to, the number of patient days for the entire hospital and the number of patient days for the area affected by the outbreak.

9. Measures taken to monitor the hospital for signs and symptoms consistent with the outbreak in patients of the hospital, including a line list.

10. For each case:

i. The date of admission and the date of discharge.

ii. Laboratory findings and investigative tests including, without being limited to, toxin testing, culture, strain typing, histopathological and colonoscopic examination, together with the results of the tests.

iii. The onset date and clinical details of signs and symptoms.

iv. The date of death and the relation of the disease to the cause of death.

v. Treatment, if any, of the disease.

vi. Complications and outcome of the disease.

vii. The place where the disease is believed to have been acquired.

viii. Risk factors.  O. Reg. 306/08, s. 1; O. Reg. 498/17, s. 5.

5.3 A report under subsection 27 (1) of the Act in respect of Carbapenemase-producing Enterobacteriaceae (CPE), infection or colonization, shall contain the following information in addition to the information required under subsection 1 (1):

1. The date of the diagnosis.

2. The agent of disease.

3. The name and address of the physician or registered nurse in the extended class attending the person.

4. The name of the hospital and the date of admission and the date of discharge if the person is admitted to hospital or the name of the hospital if the person is seen as an out-patient of the hospital.

5. The case classification of the person.

6. Laboratory findings and investigative tests, including, without being limited to, type of specimen, culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.

7. Association with outbreak and outbreak number, if applicable.

8. Risk factors, including exposure to known reservoirs or vectors, as applicable.

9. Travel history, both within and outside Canada.

10. Hospitalization history outside Canada.

11. The outcome of the disease.

12. The date of death and relation of the infection to the cause of death, if the person is deceased. O. Reg. 138/18, s. 3.

5.4 (1) Every person who performs COVID-19 point of care testing that employs nucleic acid technology and who is not otherwise required to report under the Act or this Regulation shall report every positive result to the medical officer of health of the health unit in which the person to whom the test was administered resides. O. Reg. 338/21, s. 1.

(2) Every report under this section must,

(a) contain the information required under subsection 3 (1); and

(b) be reported to the medical officer of health through the Ontario Laboratories Information System (OLIS), or if it is not possible to make the report using OLIS, be reported directly to the medical officer of health in some other secure manner. O. Reg. 157/21, s. 1.

(3) A medical officer of health who receives a report under this section shall forward it as if it were a report to which section 8 applied. O. Reg. 157/21, s. 1.

(4) In this section,

“COVID-19 point of care testing” means testing that employs a COVID-19 medical device authorized by the Minister of Health (Canada) for point-of-care use. O. Reg. 157/21, s. 1.

6. A medical officer of health who receives a report made under section 25, 26, 27 or 28, subsection 29 (2) or section 30 of the Act or section 5.4 of this Regulation shall immediately forward a copy of the report and any other information that the medical officer of health has in respect of the report to the Ministry and to the Ontario Agency for Health Protection and Promotion in a secure manner. O. Reg. 498/17, s. 6; O. Reg. 157/21, s. 2.

7. (1) A report required under subsection 38 (3) of the Act shall, with respect to the person to whom the report relates, contain the following information:

1. Name, address and telephone number in full.

2. Date of birth in full.

3. Sex.

4. The name, address and telephone number of the parent or guardian of the person experiencing the adverse event if the person is a minor.

5. The name and address of the physician or registered nurse in the extended class attending the person, the name and address of the facility where the reportable event was attended to (which may include, but is not limited to, a hospital, clinic, physician’s office or long-term care home), the date seen and the name and address of the person reporting the event.

6. If the person was admitted to hospital as a result of the reportable event, the date of admission and the date of discharge.

7. Signs and symptoms related to the reportable event and, if known, the time, date of onset and duration of each symptom related to the reportable event. 

8. The treatment prescribed, setting out drugs and dosage used, if the person sought medical care as a result of the reportable event.

9. Laboratory findings, including the dates and results of testing, other investigative procedures and medical consultation relating to the reportable event.

10. Revoked: O. Reg. 498/17, s. 7 (2).

11. The outcome of the reportable event on the date of the report; specifically, whether the person who had experienced the reportable event had fully recovered, had a residual health effect or died.

12. The name and manufacturer of the vaccine, the date and time on which the vaccine was administered, the dose, site of administration, route, lot number, expiry date and, if the vaccine has been administered as part of a series, dose number of all vaccines received prior to and potentially associated with the reportable event. For the purposes of this paragraph, “potentially associated” does not require a causal relationship between the vaccine and the reportable event.

13. Revoked: O. Reg. 498/17, s. 7 (3).

O. Reg. 1/05, s. 4; O. Reg. 426/07, s. 6; O. Reg. 498/17, s. 7 (1-3).

(2) A medical officer of health who receives a report under subsection 38 (3) of the Act shall report to the Ministry and the Ontario Agency for Health Protection and Promotion in respect of the adverse event report.  O. Reg. 1/05, s. 4; O. Reg. 498/17, s. 7 (4).

8. Any report made under the Act that is referred to in this Regulation shall be forwarded to the Ministry and the Ontario Agency for Health Protection and Promotion using the integrated Public Health Information System (iPHIS), or any other method specified by the Ministry and the Ontario Agency for Health Protection and Promotion.  O. Reg. 1/05, s. 4; O. Reg. 498/17, s. 8.

SCHEDULE 1

1. Algoma Health Unit, 99 Foster Drive, Sault Ste. Marie.

2. Anishnawbe Health Toronto, 225 Queen Street East, Toronto.

3. Bay Centre for Birth Control, Women’s College Hospital, 790 Bay Street, Toronto.

4. Birth Control & Venereal Disease Information Centre, 2828 Bathurst Street, Toronto.

5. Carlington Community and Health Services, 900 Merivale Road, Ottawa.

6. Central Toronto Community Health Centres — Queen West Site, 168 Bathurst Street, Toronto.

7. Centre francophone de Toronto, 22 College Street, Toronto.

8. Centretown Community Health Centre, 420 Cooper Street, Ottawa.

9. City of Hamilton Public Health and Community Services Department, 71 Main Street West, Hamilton.

10. Durham Region Health Department, 605 Rossland Road East, Whitby.

11. Revoked: O. Reg. 138/18, s. 4 (1).

12. Équipe de santé familiale communautaire de l’est d’Ottawa, 225 rue Donald, Ottawa.

13. Halton Region Health Department, 5353 Lakeshore Road, Burlington.

14. Hassle Free Clinic, 66 Gerrard Street East, Toronto.

15. Kensington Midwives, 340 College Street, Toronto.

16. Kingston, Frontenac and Lennox and Addington Health Unit, 221 Portsmouth Avenue, Kingston.

17. Lawrence Heights Community Health Centre, 12 Flemington Road, Toronto.

18. London InterCommunity Health Centre, 659 Dundas Street East, London.

19. Midwifery Collective of Essex County, 33 Princess Street, Leamington.

20. Municipality of Chatham-Kent Health and Family Services Public Health Unit, 435 Grand Avenue West, Chatham.

21. North Bay Parry Sound District Health Unit, 681 Commercial Street, North Bay.

22. Northwestern Health Unit, 21 Wolsley Street, Kenora.

23. Ottawa Inner City Health, 500 Old St. Patrick Street, Ottawa.

24. Ottawa Public Health Department, 179 Clarence Street, Ottawa.

25. Ottawa Valley Midwives, 130 Lansdowne Avenue, Carleton Place.

25.1 Oxford Elgin St. Thomas Health Unit, 1230 Talbot Street, St. Thomas.

26. Parkdale Community Health Centre, 1229 Queen Street West, Toronto.

27. Peel Health Department, 44 Peel Centre Drive, 2nd floor, Brampton.

28. Pinecrest-Queensway Health and Community Services, 1365 Richmond Road, Ottawa.

29. Planned Parenthood of Toronto, 36B Prince Arthur Avenue, Toronto.

30. Porcupine Health Unit, 169 Pine Street South, Timmins.

31. Region of Waterloo Public Health, 99 Regina Street South, Waterloo.

32. Regional Municipality of York, Public Health Branch, 17250 Yonge Street, Newmarket.

33. Regional Niagara Public Health Department, 573 Glenridge Avenue, Niagara Falls.

34. Rexdale Community Health Centre, 8 Taber Road, Toronto.

35. Sages Femmes Rouge Valley Midwives, 6758 Kingston Road, Toronto.

36. Sandy Hill Community Health Centre, 221 Nelson Street, Ottawa.

37. Simcoe Muskoka District Health Unit, 15 Sperling Drive, Barrie.

38. Somerset West Community Health Centre, 55 Eccles Street, Ottawa.

39. South-East Ottawa Community Health Centre, 1355 Bank Street, Ottawa.

40. Sudbury and District Health Unit, 1300 Paris Street, Sudbury.

41. Thunder Bay District Health Unit, 999 Balmoral Street, Thunder Bay.

42. Timiskaming Health Unit, 421 Shepherdson Road, New Liskeard.

43. Toronto Public Health, 277 Victoria Street, Toronto.

44. Transitions for Youth, 3365 Harvester Road, Burlington.

45. Wabano Centre for Aboriginal Health, 299 Montreal Road, Vanier.

46. Wassay Gezhig Na Nahn Dah We Igamig, 4th Avenue South, Kenora.

47. Wellington-Dufferin-Guelph Health Unit, 8460 Wellington Road #19, Belwood.

48. Windsor Regional Hospital, Metropolitan Campus, 1995 Lens Avenue, Windsor.

49. Windsor-Essex County Health Unit, 1005 Ouellette Avenue, Windsor.

50. Women’s Health in Women’s Hands, 2 Carlton Street, Toronto.

O. Reg. 274/07, s. 1; O. Reg. 138/18, s. 4.

Forms 1, 2 Revoked: O. Reg. 1/05, s. 5.

Form 3 Revoked: O. Reg. 148/17, s. 3.